MedTrace Logo

Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

NCT00395551 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-01-08

No results posted yet for this study

Summary

The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.

Conditions

  • Choroidal Neovascularization

Interventions

DRUG

ranibizumab

0.5mg intravitreal injection

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Ophthalmic Consultants of Boston

    lead OTHER

Principal Investigators

  • Jeffrey S Heier, M.D. · Ophthalmic Consultants of Boston

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2009-06-30
Completion
2009-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395551 on ClinicalTrials.gov